News

FDA grants Celgene's Revlimid new use as it moves toward $10B in sales

Celgene's powerhouse cancer drug Revlimid generated nearly $5 billion for the company last year and has now gotten yet another FDA nod which analysts believe will help it double that amount within 5 years.

Regeneron's Eylea beats Roche's Lucentis in new head-to-head study

Regeneron's eye drug Eylea picked up steam against two competing products from Roche, as the first head-to-head study comparing the meds found that Eylea outperformed Lucentis and Avastin in treating moderate to severe vision loss in patients with diabetic macular edema.

NICE, drugmakers reject analysis that price watchdog is too generous

Drugmakers are often at odds with the National Institute for Health and Care Excellence (NICE) in England, saying it is stingy in what it will approve as payments for their best new treatments. But the industry and the gatekeeper have pulled together in defending against a study that says NICE is paying drugmakers too much for their best new treatments.

Pharma wanted pricey orphan meds, and now it's got 'em in record numbers

New drug approvals were up last year, and orphan drug approvals were no exception. But by just how much did they climb? The FDA Law Blog has done some digging through the agency's Orphan Drug Designations and Approvals database, and it's got an answer.

Who's the new king of the drug launch hill? Hint: It's all in the Gilead family

Move over, Sovaldi--there's a new launch king in town. And luckily for Gilead, it's another of its own. Harvoni has officially unseated its hep C predecessor, putting up sales figures and script numbers that beat Sovaldi's at this point in its launch.

Amphastar pays some rebates after price of overdose drug doubles

Police and public safety departments around the country have been stocking up on naloxone from Amphastar Pharmaceuticals and other makers as a way to fight heroin and painkiller overdoses. But with prices for the drug doubling in the last year, some are accusing the small California company of overpricing the overdose drug and are asking for some of their money back.

Remicade's U.S. patent rejection could open up early rivalry with Celltrion biosim

The U.S. Patent Office gives, and the U.S. Patent Office takes away. Unfortunately for Johnson & Johnson, it was the latter for Remicade. After a re-examination of Remicade's September 2018 patent, agency officials issued a big fat rejection.

Pharma's top 10 M&A deals of 2014

2014 was quite the banner year for pharma M&A. According to EY's annual firepower report, deals topped $200 billion--well over twice the average volume from over the past decade.

Why call us Allergan? Because brands are the name of Actavis' new game

Actavis has been working to boost its branded drug sales and shift its identity from a generics maker to a company that houses both branded and copycat meds under one roof. In case there's any confusion about the path it's chosen, it's taking on the name of its latest branded buy.

Here's a switcheroo: HIV activists target Gilead for holding back on Truvada marketing

Gilead Sciences is no stranger to criticism. Consider the years-long outcry over HIV and hep C drug prices. But now the California-based company finds itself in a strange--yet somehow familiar--spotlight. At a time when the pharma industry is drawing fire for marketing its drugs to doctors, Gilead is drawing fire for not marketing enough.

Say what? CVS Health execs figure PCSK9 meds to cost up to $150B

CVS Health is raising eyebrows with a new estimate: A coming class of pricey cholesterol meds could cost the U.S. as much as $150 billion per year.

Boehringer's sales slide triggers job-chopping in Connecticut

Boehringer Ingelheim's global restructuring--prompted by the German pharma's sales struggle--is now manifesting itself in Connecticut, where the company is laying off staffers in Ridgefield.

Endo said to be jousting with Valeant, Shire to win Salix

With Valeant and Shire already said to be prepping bids for North Carolina's Salix, it seems there's a third wannabe suitor, too. Word on the street is that Endo International has come calling multiple times--and though Salix has shot Endo down, it's still not going away.

Shanghai official linked to GSK bribery sentenced to 19 years in prison

The GlaxoSmithKline officials accused of orchestrating its $489 million Chinese bribery scandal may have dodged prison sentences in the country, but a Shanghai health official linked to the British pharma won't be so lucky.

Glaxo's Connelly bows out amid scramble to turn around U.S. business

GlaxoSmithKline's sputtering U.S. sales gave the company a black eye with investors. Now, the company's U.S. chief is stepping down. Deirdre Connelly is out the door, the company told employees on Tuesday, with SVP Jack Bailey rising to take her place.

Le Figaro: Sanofi will tap Bayer's Brandicourt as CEO this week

Olivier Brandicourt is the man. Sanofi will officially hand the reins to Brandicourt this week, Le Figaro reports, ending months of speculation about the French drugmaker's new CEO. Now heading up Bayer HealthCare, Brandicourt has reportedly been on Sanofi's short list since ex-CEO Chris Viehbacher made his untimely exit--or perhaps before.

Bayer's Brandicourt said to top Sanofi CEO list: Bloomberg

Sanofi Chairman Serge Weinberg recently brushed away suggestions that the French drugmaker was having a hard time finding someone who wanted to be CEO of the company. Now the talk is that Bayer's Olivier Brandicourt, who is also a Pfizer alum, is the top contender.

Gilead strikes Sovaldi price deal in Germany as it picks up speed in EU

Just days after Gilead COO John Milligan told investors to expect negotiations for its hep C franchise to unfold very quickly in Europe, Germany has said it has a deal to buy Sovaldi at €41,000 for a 12-week course. That is deeply discounted from the initial price of €56,500 with which the company started.

Eisai nabs quick FDA blessing for cancer blockbuster hopeful Lenvima

Eisai grabbed an early green light on Friday from U.S. regulators for thyroid cancer drug Lenvima, meaning the Japanese pharma can now get an earlier-than-expected start on trying to make its blockbuster dreams a reality.

Activists ready to fight for Ariad CEO's ouster: CNBC

Industry-watchers knew a shake-up could be in Ariad Pharmaceuticals' future when Alex Denner, founder of activist hedge fund Sarissa Capital and protégé of notorious corporate raider Carl Icahn, took a seat on the company's board of directors last year. Now, a proxy brawl looks to be around the corner.